ÂÜÀòÂÒÂ×

Karen Liu is a seasoned professional in the life sciences sector, currently serving as a Partner at 3E Bioventures since June 2015, where the focus is on investing in groundbreaking health innovations across biotech and TechBio. Liu holds multiple board member positions, including roles at Biosion, Dermaliq Therapeutics, Neural Galaxy, SHANTON PHARMA, Rapafusyn Pharmaceuticals, Purinomia Biotech, Avirmax, Ansun Biopharma, and Quadriga BioSciences, contributing to a range of developments from antibody drug discovery to next-generation gene therapies. Academic credentials include a Ph.D. in Immunology from Harvard University, a Master of Medical Sciences from Harvard Medical School, a B.S. in Biochemistry from Cornell University, and an EMBA in Management from Cheung Kong Graduate School of Business.